Annals of Military and Health Sciences Research
Volume 20 · Issue 3 · e130618
OPEN PEER REVIEW

Efficacy of Ciprofloxacin in Prevention of Sepsis Among the Patients with Chemotherapy-Induced Neutropenia: A Randomized Double-Blind Clinical Trial in a University Hospital in Tehran, Iran

Ali Asgari, Reza Ghalehtaki, hadi ranjbar, Hassan Jalaeikhoo, Ramin Hamidi-Farahani, Mohammad Hassan Kazemi-Galougahi, Saeed Soleiman-Meigooni

SUBMITTED	ACCEPTED	DOI
8 Aug 2022	25 Aug 2022	10.5812/amh-130618

About this report

This open peer review (OPR) report shows the public comments made on this article during peer review, by the reviewers, the associate editor and the editor-in-chief, for every revision round, together with the authors' replies. Comments appear only with the consent of the people who wrote them. Reviewers who chose to sign their report are named; the others are shown as "Referee". Comments are edited for language only, and confidential remarks to the editors are not included.

More about open peer review: brieflands.com/knowledgebase/opr

Contents

1 **Original submission** Referee 1, Associate Editor, Editor-in-Chief 2

1 Original submission

3 comments · 21 Aug 2022 – 25 Aug 2022

Referee 1 Reviewer

ACCEPT 21 Aug 2022

Dear EIC:
This manuscript reports a randomized double-blind clinical trial exploring ciprofloxacin's efficacy in preventing bacterial infections in chemotherapy-induced neutropenia. It is a well-written manuscript, and the data-gathering methods are reasonably satisfactory to address the aim of the study. The results show that ciprofloxacin significantly reduces fever (FN) but does not alter the mortality rate.
There are some suggestions for further improvement of the manuscript:
1- I suggest that the authors mention the current approval status of ciprofloxacin for the treatment of bloodstream septicemia.
2- The authors should define the manuscript abbreviations at the beginning (as a list) or when they are first used.
3- The authors should report possible side effects of ciprofloxacin administration for preventing bacterial infections in chemotherapy-induced neutropenia, especially possible musculoskeletal adverse effects of ciprofloxacin.
4- There are two abstracts; one is on page one, and the other is on page 4, so the first must be removed.

Sincerely

Associate Editor

ACCEPT 24 Aug 2022

Dear EIC:
This manuscript reports a randomized double-blind clinical trial exploring Ciprofloxacin's efficacy in preventing bacterial infections in Chemotherapy-Induced Neutropenia. It is a well-written manuscript, and the data gathering methods are reasonably satisfactory to address the aim of the study. The results show that Ciprofloxacin significantly reduces fever (FN) but does not alter the mortality rate.
There are some suggestions for further improvement of the manuscript:
1- I suggest that the authors mention the current approval status of Ciprofloxacin for the treatment of bloodstream septicemia.
2- The authors should define the manuscript abbreviations at the beginning (as a list) or when they are first used.
3- The authors should report possible side effects of Ciprofloxacin administration for preventing bacterial infections in Chemotherapy-Induced Neutropenia, especially possible musculoskeletal adverse effects of Ciprofloxacin.
4- There are two abstracts: one is on page one, and the other is on page 4, so the first must be removed.
Sincerely

Editor-in-Chief

ACCEPT 25 Aug 2022

accept